OrbusNeich Medical said it got the green light in Europe for its Combo dual-therapy stent, calling it the 1st such device to both promote healthy tissue growth and prevent the stent from being engulfed by tissue growth.
The Combo device combines Ft. Lauderdale- and Hong Kong-based OrbusNeich’s "pro-healing technology" and the anti-cell growth drug sirolimus, according to a press release. The sirolimus drug is desinged to elute completely 90 days after implantation, Orbus said, touting reduced time on anti-platelet drugs as a major benefit from the stent.
"Combo was designed to address the limitations of DES monotherapy associated with delayed or impaired healing. With this new technology, we have a stent that combines sustained control of smooth cell proliferation with accelerated vascular healing driven by our EPC capture technology," Stephen Rowland, VP of R&D, said in a statement.